drugset / Trial / NCT02208583
Molecular Phenotype Changes and Personalized Treatment for CRPC
Non-randomizedSingle-groupOpen-label
Summary
To explore the molecular phenotypic changes and personalized treatment in castration-resistant prostate cancer.
Timeline
- Start
- 2014-06
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Celecoxib | Other / unclassified | — | Oral |
| Comparator | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | — |
| Comparator | Everolimus | Small molecule | — | Oral |
| Comparator | Gefitinib | Small molecule | — | Oral |
| Comparator | Lapatinib | Small molecule | — | Oral |
| Comparator | Prednisone | Other / unclassified | 5 mg | — |
| Comparator | Sunitinib | Small molecule | — | Oral |
| Comparator | Vemurafenib | Small molecule | — | Oral |